ELISA/assay

Human Glial Fibrillary Acidic Protein (GFAP) ELISA Kit

MBS2701011

24-Strip-Wells

210 USD

ELISA Kit

Human Glial Fibrillary Acidic Protein (GFAP) ELISA Kit

[Glial Fibrillary Acidic Protein (GFAP)]

[Intermediate Filament Protein]

[glial fibrillary acidic protein; Glial fibrillary acidic protein; glial fibrillary acidic protein; glial fibrillary acidic protein]

[GFAP]

[GFAP; GFAP; ALXDRD; GFAP]

Human

432

This assay has high sensitivity and excellent specificity for detection of GFAP. No significant cross-reactivity or interference between GFAP and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Typical Testing Data/Standard Curve (for reference only)

Samples: Human Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids. Assay Type: Quantitative Sandwich. Detection Range: 0.156-10ng/mL. Sensitivity: 0.056ng/mL.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level GFAP were tested 20 times on one plate, respectively. Intra-Assay: CV<10%. Inter-assay Precision: Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level GFAP were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100. Inter-Assay: CV<12%

Intended Uses: The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of GFAP in human serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids. Principle of the Assay: The microplate provided in this kit has been pre-coated with an antibody specific to GFAP. Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to GFAP. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain GFAP, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm +/- 10nm. The concentration of GFAP in the samples is then determined by comparing the O.D. of the samples to the standard curve.

251802

AAB22581.1

P14136

49,508 Da

Neural Crest Differentiation Pathway (672460); Nuclear Signaling By ERBB4 Pathway (530744); Signal Transduction Pathway (477114); Signaling By ERBB4 Pathway (530741); Spinal Cord Injury Pathway (739007)

This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]

GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.

24-Strip-Wells

210 USD

48-Strip-Wells

330

96-Strip-Wells

440

5x96-Strip-Wells

1800

10x96-Strip-Wells

3345